Gilead, LEO Pharma Partner in $1.7 Billion Deal for Inflammatory Disease Therapies
A statement from Gilead indicates that the deal is likely to lower its 2025 GAAP and non-GAAP earnings per share by $0.15 to ...
GlobalData on MSN6d
Gilead and LEO Pharma link on programmes for inflammatory conditions
Gilead Sciences and LEO Pharma have entered a strategic collaboration to expedite the development and commercialisation of ...
PharmaTimes6d
Gilead and LEO Pharma partner to develop oral STAT6 program
Gilead Sciences and LEO Pharma have announced a strategic partnership to advance LEO Pharma’s oral STAT6 program. This ...
BioSpace6d
Gilead Continues Diversification Drive With Potential $1.7B Inflammation Pact With LEO
Gilead’s investment will let it assess the therapeutic potential of targeting STAT6, a transcription factor involved in IL-4 ...
devdiscourse6d
Major Pharmaceutical Mergers and Developments Shake Up the Industry
Major moves in the pharmaceutical industry include Ownership Matters recommending support for the Chemist Warehouse-Sigma Healthcare merger, J&J's potential bid for Intra-Cellular Therapies, and ...
Contract Pharma6d
Gilead, LEO Pharma Partner to Accelerate Development of Oral STAT6 Program
Gilead Sciences Inc. and LEO Pharma have partnered to accelerate the development and commercialization of LEO Pharma’s small ...
The Pharma Letter6d
Gilead partners with LEO Pharma on oral STAT6 program
Gilead Sciences and Danish dermatology specialist LEO Pharma announced a strategic partnership, marking another move outside ...